Aytu biopharma reports fiscal third quarter 2021 financial results and recent business highlights

- closed merger with neos therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - added late-stage pediatric onset rare disease asset, protein kinase c Β isoform (pkcΒ) inhibitor, ar101 (enzastaurin) to development pipeline - - record quarter for consumer health division with revenue reaching $8.4 million and rx division revenue up 9% over same quarter last year - - grew leadership team with three executives including cfo, rich eisenstadt - - management to host live conference call and webcast today at 4:30 p.m. et - englewood, co / accesswire / may 17, 2021 / aytu biopharma, inc. (nasdaq:aytu), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for the fiscal third quarter ended march 31, 2021 and provided recent business highlights.
AYTU Ratings Summary
AYTU Quant Ranking